Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
MOG 0.390 +2.6% S 0.115 −25.8% OMI 0.305 −3.2% BMM 3.77 −0.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.940 −6.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.260 −1.9% GAL 0.400 +0.0% LIB 0.780 −14.3% MOG 0.390 +2.6% S 0.115 −25.8% OMI 0.305 −3.2% BMM 3.77 −0.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.940 −6.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.260 −1.9% GAL 0.400 +0.0% LIB 0.780 −14.3%
Management

Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

By The Northwire Desk — AI Analysis Mar 26, 2026 · 08:00 QNTM · 6.0 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma announced the appointment of Dr. Salvatore Napoli, MD, as Principal Investigator for its planned Phase 2 trial of Lucid‑MS, an investigational therapy targeting demyelination in multiple sclerosis (MS).
  • The company intends to file an Investigational New Drug (IND) application with the FDA in the coming weeks, pending regulatory clearance.
  • Management highlighted the appointment as a key milestone toward advancing Lucid‑MS into clinical evaluation and addressing unmet medical needs in MS.

Key Details

  • Appointment: Dr. Salvatore Napoli, internationally recognized neurologist and KOL in MS, will serve as Principal Investigator for the Phase 2 trial of Lucid‑MS.
  • Trial Planning: Quantum BioPharma plans to submit an IND application for Lucid‑MS to the FDA within weeks; the IND includes the design of the upcoming Phase 2 study.
  • Therapeutic Candidate: Lucid‑MS is a first‑in‑class, non‑immunomodulatory, neuroprotective compound (patented NCE) that has demonstrated prevention of demyelination in preclinical models.
  • Regulatory Pathway: Subject to FDA clearance of the IND, the Phase 2 trial will evaluate efficacy, safety, and tolerability of Lucid‑MS in people with MS.
  • Management Comments:
  • Andrzej Chruscinski (VP, Scientific & Clinical Affairs) emphasized Dr. Napoli’s expertise as vital for clinical evaluation.
  • CEO Zeeshan Saeed called the appointment a “key milestone” and underscored the program’s potential to address high unmet need in neurodegenerative disease.
  • Strategic Context: The announcement follows Quantum BioPharma’s broader focus on neurodegenerative and metabolic disorders, including its subsidiary Lucid Psycheceuticals Inc., which holds rights to Lucid‑MS.

Notable Quotes

“We are pleased to collaborate with Dr. Napoli as we advance our clinical development program,” – Andrzej Chruscinski, Vice‑President, Scientific and Clinical Affairs.

“The appointment of Dr. Napoli represents a key milestone as we advance Lucid‑MS toward clinical evaluation.” – Zeeshan Saeed, CEO.

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other